Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-25
2005-01-25
Romeo, David (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C530S345000, C930S021000
Reexamination Certificate
active
06846803
ABSTRACT:
The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine. The present invention also relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acids of native sauvagine, wherein the N-terminal amino acid of said antagonist is a charged amino acid. Furthermore, the present invention relates to a polynucleotide encoding the antagonist of the present invention, a vector comprising the polynucleotide of the present invention, and a host comprising the polynucleotide or the vector of the present invention. Also described are a method for producing the antagonist of the present invention, antibodies directed the antagonist of the present invention, as well as anti-idiotypic antibodies directed against the antibody of the present invention. The present invention also relates to pharmaceutical and diagnostic compositions comprising the antagonist, the polynucleotide, the vector, the antibody, and/or the anti-idiotypic antibody of the present invention. Furthermore, the present invention relates to a kit comprising one or more of the above mentioned compounds of the present invention and to the use of one or more of these compounds for the preparation of a pharmaceutical composition for preventing and/or treating a Corticotropin-Releasing Factor Receptor, type 2 (CRFR2)-associated disease.
REFERENCES:
patent: 4474765 (1984-10-01), de Castiglione et al.
patent: 5464757 (1995-11-01), Potter et al.
patent: 5874227 (1999-02-01), Rivier
Lovenberg et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A. Jan. 31, 1995;92(3):836-40. Erratum in: Proc Natl Acad Sci U S A Jun. 6, 1995;92(12):5759.*
Gonzalez et al., Cell and Tissue Research, vol. 283, No. 1, pp. 117-123 (1996).
Gaudino et al., Peptides, vol. 6, Suppl. 3, pp. 209-213 (1985).
Lovenberg et al., Curr. Pharm. Des., vol. 1, No. 3, pp. 305-316 (1995).
Spiess et al., Trends Endocrinol. Metab., vol. 9, No. 4, pp. 140-145 (1998).
Behan et al., Mol. Psychiatry, vol. 1, No. 4, pp. 265-277 (1996).
Ruhmann et al., Proceeding of the Nat'l Acad. of Sciences of the USA, vol. 95, No. 26, pp. 15264-15269 (1998).
Ruhmann Andreas
Spiess Joachim
Birch & Stewart Kolasch & Birch, LLP
Max Planck Gesellschaft zur Forderung der Wissenschaften E.V.
Romeo David
LandOfFree
Antagonists specific for the corticotropin-releasing factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists specific for the corticotropin-releasing factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists specific for the corticotropin-releasing factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3394882